GT719 cell therapy for immune kidney diseases
Part of Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a universal cell therapy called GT719 that targets CD19 on B cells to treat several immune-mediated kidney diseases, including IgA nephropathy, ANCA vasculitis, membranous nephropathy, and others. It may help people who have not responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have one of these kidney diseases: IgA nephropathy, ANCA vasculitis, membranous nephropathy, podocytopathy, or PGNMID.
- Your kidney disease must be considered high risk or not responding to standard treatments.
- You must have CD19 positive B cells in your blood.
- You cannot have active infections, certain heart or lung problems, or a history of organ transplant.
- You must agree to use effective birth control for at least one year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This early-stage trial tests a new type of immune cell therapy (CAR-γδ T cells) designed to treat three types of autoimmune kidney disease that haven't responded well to standard treatments. The goal is to see if this experimental therapy can reduce kidney damage and help patients avoid kidney failure.
This trial tests a new treatment using special immune cells (called STAR-T cells) to help people with two types of autoimmune kidney disease: IgA nephropathy and primary membranous nephropathy. The goal is to see if this therapy can reduce kidney damage and improve symptoms.
This study tests a new cell therapy (IM19 CAR-T) for people with two types of kidney disease: IgA nephropathy or primary membranous nephropathy. The goal is to see if these specially engineered immune cells can reduce kidney damage and slow down the disease.
This trial is testing a new therapy made from your own immune cells (called CAR NK cells) that are designed to fight a type of kidney disease that hasn't responded to standard treatments. It may be an option if you have membranous nephropathy, IgA nephropathy, or ANCA-associated vasculitis and previous treatments have failed.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.